Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT02727608 Completed - Diabetes Mellitus Clinical Trials

Complement Inhibitor Eculizumab in Clinical Islet Transplantation

ICC
Start date: May 15, 2016
Phase: Phase 2
Study type: Interventional

This is a dual centre, single arm, exploratory study of the possibility to use eculizumab (Soliris) to prevent/reduce destruction of islets of Langerhans after portal infusion of the islets in patients with diabetics accepted for islet transplant.

NCT ID: NCT02726425 Completed - Diabetes Mellitus Clinical Trials

Women in Control: A Virtual World Study of Diabetes Self-Management

Start date: July 2015
Phase: N/A
Study type: Interventional

This study evaluates the comparative effectiveness of a diabetes self management (DSM) group medical visit in the virtual world (Second life) verses a face-to-face format, aimed to increase physical activity and improve glucose control among Black/African American and Hispanic women with uncontrolled diabetes mellitus.

NCT ID: NCT02726217 Completed - Diabetes Clinical Trials

NYULMC CareSmarts Pilot

Start date: March 1, 2016
Phase: N/A
Study type: Interventional

CareSmarts is a theory-driven behavioral intervention designed to improve self-care among patients with Type 2 diabetes (T2D) with poor glycemic control (HbA1c>8%), through multiple mediators, including cuing, education, self-efficacy, social support, and health beliefs. Individuals will be randomly assigned with equal allocation to either the CareSmarts intervention or to usual care for 6 months.

NCT ID: NCT02726100 Completed - Hypertension Clinical Trials

SMARTHealth Diabetes in China Using Lay Family Health Promoters

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

It's a community-based parallel-arm cluster Randomized Controlled Trial (RCT). An interactive mobile health management system will be developed to support lay family health promoters and healthcare staff to improve clinical outcomes for family members with Type 2 Diabetes Mellitus (T2DM). 2,000 participants from 80 sites will be chosen from urban (40 communities) and rural (40 villages) settings in Shijiazhuang City, Hebei Province.

NCT ID: NCT02724566 Completed - Diabetes Clinical Trials

Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers

APELINS-2
Start date: May 2016
Phase: Phase 1
Study type: Interventional

Preclinical studies have demonstrated in mouse models that (PYR1)-apelin-13 exerts a glucose-regulating action in vivo. The (PYR1)-apelin-13 effect on insulin sensitivity in healthy overweighed volunteers has been previously assessed in a phase I clinical trial (APELINS study; NCT02033473). The APELINS-2 clinical trial aims to expand the initial proof of concept to the population targeted by future innovative insulin-sensitizing therapies: patients living with type 2 diabetes.

NCT ID: NCT02722499 Completed - Diabetes Mellitus Clinical Trials

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

FITEST
Start date: March 2016
Phase: N/A
Study type: Interventional

The aim of this study is to test the efficacy of financial incentives augmented telephone-delivered diabetes education and skills training intervention in improving HbA1c levels in African Americans (AA) with type 2 diabetes (T2DM).

NCT ID: NCT02722239 Completed - Clinical trials for Diabetes Mellitus, Type 2

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Start date: March 30, 2016
Phase: Phase 1
Study type: Interventional

The aim of this study is to demonstrate bioequivalence of fixed dose combination Dapagliflozin + Metformin modified -release, film-coated tablets, 10 mg + 1000 mg, (AstraZeneca AB, Sweden) versus Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), ER tablets, 1000 mg (2 x 500 mg) (Merck Santé S.A.S., France) which are already registered in the Russian Federation.

NCT ID: NCT02718703 Completed - Diabetes Mellitus Clinical Trials

Project EV Minus Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation

Start date: February 2015
Phase: N/A
Study type: Interventional

Clinical Evaluation including System Accuracy, User Performance and System Use Evaluation of a new Blood Glucose Monitoring System.

NCT ID: NCT02718638 Completed - Hypertension Clinical Trials

Effects of Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients

Hemodialysis
Start date: January 2013
Phase: N/A
Study type: Interventional

Oxidative stress and inflammation are cardiovascular risk factors in patients with chronic kidney disease (CKD) undergoing hemodialysis (HD). Nuclear transcription factors play roles in the coordinated expression of genes involved in inflammation, such as nuclear factor Kappa B (NFkB) that increase the cytokines synthesis and Nuclear factor erythroid 2-related factor 2 (Nrf2) that increase the transcription of genes encoding enzymes of phase II detoxifying and antioxidant enzymes. The aim of this study was to evaluate the effects of resistance exercise program on the expression of transcription factors Nrf2 and NF-kB in HD patients.

NCT ID: NCT02716623 Completed - Diabetes Mellitus Clinical Trials

The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer

DEAL
Start date: March 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to learn if bladder cancer patients can follow a diet and exercise program during treatment and whether the program will improve results of their treatment.